Compare BABA & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BABA | AZN |
|---|---|---|
| Founded | 1999 | 1992 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.4B | 250.7B |
| IPO Year | 2014 | 1995 |
| Metric | BABA | AZN |
|---|---|---|
| Price | $109.24 | $158.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 40 | 11 |
| Target Price | $185.41 | ★ $211.35 |
| AVG Volume (30 Days) | ★ 6.1M | 2.6M |
| Earning Date | 11-24-2026 | 10-30-2026 |
| Dividend Yield | 0.95% | ★ 2.06% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.63 | $7.55 |
| Revenue Next Year | $12.82 | $6.07 |
| P/E Ratio | ★ $21.20 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $91.99 | $80.48 |
| 52 Week High | $182.50 | $212.71 |
| Indicator | BABA | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 41.72 |
| Support Level | $107.20 | $154.89 |
| Resistance Level | $121.13 | $169.77 |
| Average True Range (ATR) | 2.23 | 2.87 |
| MACD | 0.16 | -0.77 |
| Stochastic Oscillator | 18.87 | 25.58 |
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China retail e-commerce platform is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China wholesale e-commerce, international retail and wholesale e-commerce, local consumer services, travel services, cloud computing, digital media and entertainment, Cainiao logistics services, and other businesses.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.